Addressing Challenges in BCG-Unresponsive NMIBC: Overview and Unmet Needs

Max Kates, MD, discusses how BCG-unresponsive non-muscle invasive bladder cancer patients historically faced limited treatment options beyond radical cystectomy, with significant unmet needs in preserving bladder function while effectively treating this aggressive disease.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Overview of BCG-Unresponsive NMIBC

EP: 2.Challenges of BCG-Unresponsive NMIBC

EP: 3.Standard Treatment Options for BCG-Unresponsive NMIBC

EP: 4.Unresponsive NMIBC: Gene Therapies

EP: 5.Gene Therapy Considerations for BCG-Unresponsive NMIBC

EP: 6.Gene Therapy Data for BCG-Unresponsive NMIBC

EP: 7.BCG-Unresponsive NMIBC: Insights for Newer Treatment Modalities

Now Viewing

EP: 8.Addressing Challenges in BCG-Unresponsive NMIBC: Overview and Unmet Needs

EP: 9.Current Treatment Options for BCG-Unresponsive NMIBC

EP: 10.The Impact of Targeted Gene Therapy and Nadofaragene Firadenovec on BCG-Unresponsive NMIBC

EP: 11.Advancements in BCG-Unresponsive NMIBC and the Impact of Trial Results and Long-Term Follow-Up

EP: 12.Discussing Treatment Options for BCG-Unresponsive NMIBC

EP: 13.Cost-Effectiveness and Patient Support in Treating BCG-Unresponsive NMIBC

EP: 14.Reducing Resource Expenditure in Clinics with New Gene Therapies for BCG-Unresponsive NMIBC

EP: 15.Enhancing Access to BCG-Unresponsive NMIBC Treatments

EP: 16.Navigating BCG-Unresponsive NMIBC and Emerging Therapies

EP: 17.The Impact of Gene Therapy and Advancements in BCG-Unresponsive NMIBC Treatment

EP: 18.BCG-Unresponsive NMIBC: Balancing Care and Financial Considerations

EP: 19.Navigating Treatment Choices and Financial Considerations in BCG-Unresponsive NMIBC

EP: 20.Adoption of New Treatments for BCG-Unresponsive NMIBC

EP: 21.Future Directions of BCG-Unresponsive NMIBC Management

1. Would you please start by giving a brief overview of BCG-unresponsive NMIBC? Nonmuscle Invasive Bladder Cancer
2. Prior to recent therapeutic innovations in the bladder space what challenges or unmet needs did you face when treating these patients?

Related Videos

Future Directions of BCG-Unresponsive NMIBC Management

Adoption of New Treatments for BCG-Unresponsive NMIBC

Navigating Treatment Choices and Financial Considerations in BCG-Unresponsive NMIBC

BCG-Unresponsive NMIBC: Balancing Care and Financial Considerations

The Impact of Gene Therapy and Advancements in BCG-Unresponsive NMIBC Treatment

Navigating BCG-Unresponsive NMIBC and Emerging Therapies

Enhancing Access to BCG-Unresponsive NMIBC Treatments

Reducing Resource Expenditure in Clinics with New Gene Therapies for BCG-Unresponsive NMIBC

Cost-Effectiveness and Patient Support in Treating BCG-Unresponsive NMIBC

Discussing Treatment Options for BCG-Unresponsive NMIBC